NCT00669669 2022-05-18
O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
Clinical Trials
7 trialsNCT00436436 2017-03-28
O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00086970 2013-01-24
Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00003613 2013-01-11
O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00389090 2012-02-09
A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
Keryx / AOI Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00003567 2010-06-11
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT00045721 2009-10-16
Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma
Pediatric Brain Tumor Consortium
Phase 1 Terminated